Olmesartán Alter (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olmesartán Alter, is an angiotensin II receptor blocker presented as a tablet for oral use. It is employed to lower elevated blood pressure in adults, including those with associated cardiovascular risk factors.

GNH USA supplies Olmesartán Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil acts on the renin‑angiotensin system to manage arterial hypertension and related conditions. - Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Hypertension with type 2 diabetes: helps control blood pressure and may protect renal function. - Hypertension in chronic kidney disease: lowers blood pressure while supporting kidney health.

Olmesartan medoxomil may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness: light‑headed sensation, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nasal congestion: blocked or runny nose. - Diarrhea: loose stools occurring intermittently. - Cough: dry, non‑productive throat irritation.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat requiring urgent care. - Hyperkalemia: elevated potassium levels that may affect heart rhythm. - Acute renal failure: sudden decline in kidney function. - Severe hypotension: markedly low blood pressure causing fainting. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Myocardial infarction: rare occurrence of heart attack symptoms.

Before initiating therapy with Olmesartan medoxomil, several safety considerations should be observed. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: evaluate serum creatinine and eGFR periodically. - Electrolyte balance: check potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy avoidance: contraindicated in the second and third trimesters due to fetal risk. - Elderly caution: start at lower doses and monitor for orthostatic hypotension. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil can interact with several medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - ACE inhibitors or other ARBs: combined use may cause additive hypotension and renal impairment. - Potassium‑sparing diuretics or supplements: increase risk of hyperkalemia. - Lithium: may raise lithium concentrations, leading to toxicity. - NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and affect renal function. - Aliskiren (in diabetic patients): heightened risk of adverse renal outcomes.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustment. - CYP450 inhibitors (e.g., ketoconazole): could modestly increase olmesartan levels. - Other antihypertensives (beta‑blockers, calcium channel blockers): monitor for excessive hypotension. - Antacids containing aluminum or magnesium: may reduce absorption if taken simultaneously.